Biofrontera Inc. (NASDAQ:BFRI) Sees Significant Increase in Short Interest

Biofrontera Inc. (NASDAQ:BFRI) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 464,825 shares, an increase of 82.1% from the August 31st total of 255,272 shares. Approximately 3.4% of the company’s shares are sold short. Based on an average daily trading volume, of 1,042,222 shares, the short-interest ratio is presently 0.4 days.

Analyst Ratings Changes

Several research firms have recently weighed in on BFRI. Wall Street Zen downgraded shares of Biofrontera from a “buy” rating to a “hold” rating in a research report on Sunday, September 20th. Weiss Ratings upgraded shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Finally, Zacks Research raised shares of Biofrontera from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold”.

Biofrontera Price Performance

NASDAQ BFRI traded down $0.02 on Tuesday, reaching $1.11. The company’s stock had a trading volume of 77,654 shares, compared to its average volume of 419,480. The business has a 50-day moving average price of $1.32 and a 200 day moving average price of $1.10. Biofrontera has a 52 week low of $0.55 and a 52 week high of $1.66. The firm has a market cap of $16.44 million, a PE ratio of -2.47 and a beta of 0.83. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.78.

Biofrontera (NASDAQ:BFRI) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.05. Biofrontera had a negative net margin of 13.78% and a negative return on equity of 145.81%. The firm had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $9.50 million. Sell-side analysts expect that Biofrontera will post -0.6 EPS for the current year.

About Biofrontera

Biofrontera Inc (NASDAQ:BFRI) is a commercial-stage biopharmaceutical company focused on dermatology. The company develops and markets prescription therapies for the treatment of skin conditions, with an emphasis on products that address actinic keratosis and other dermatologic diseases.

Its principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, which is used in combination with the BF-RhodoLED lamp in photodynamic therapy for actinic keratoses. Biofrontera also provides the BF-RhodoLED photodynamic therapy lamp system used by healthcare professionals to activate the treatment.

Biofrontera Inc is based in the United States and operates as part of the broader Biofrontera corporate group, which has German roots and an international dermatology business.